A REVIEW ON UTILISATION OF REMDESIVIR IN TREATING COVID  19 : THERAPEUTIC REPURPOSING AND UNMET CLINICAL NEEDS

Savithri Somala; Bhavani Yelicherla; Salma Shaik

doi:10.31838/ijprt/12.02.05

2022, Vol: 12, Issue: 2

12 / 2Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

« Previous Article

Review Article

IJPRT. 2022; 12(2): 32-38

doi: 10.31838/ijprt/12.02.05

A REVIEW ON UTILISATION OF REMDESIVIR IN TREATING COVID 19 : THERAPEUTIC REPURPOSING AND UNMET CLINICAL NEEDS

Savithri Somala, Bhavani Yelicherla, Salma Shaik.

Abstract
Remdesivir is the first drug that has been approved by the US Food and Drug Administration (FDA) for clinical use in hospitalized patients with COVID-19 illness. Remdesivir is a broad-spectrum antiviral agent that has previously demonstrated antiviral activity against filoviruses (Ebola viruses,Marburg virus), coronaviruses (SARS-CoV, MERS-Co-V, SARS-CoV-2), paramyxoviruses and Pnemoviridae . Remdesivir was initially developed against the Ebola virus based on its antiviral properties demonstrated in vitro and in vivo in animal models but failed to demonstrate efficacy in randomized clinical trials. Remdesivir was shown to exhibit antiviral activity against SARS-CoV-2 in vitro studies, and it was proposed as an investigational drug early during the pandemic. However,based on data from randomized clinical trials that demonstrated superior clinical efficacy of remdesivir to placebo, remdesivir is the first and only available therapeutic drug that has been approved by the US Food and Drug Administration (FDA) for clinical use in the management of patients with severe suspected or laboratory-confirmed COVID-19. COVID -19 is a disease caused by SARS-CoV-2 that can trigger what doctors call a respiratory tract infection. It can affect your
upper respiratory tract (sinuses, nose, and throat) or lower respiratory tract (windpipe
and lungs).It spreads the same way other coronaviruses do, mainly through person-to-person
contact. Infections range from mild to deadly.

Key words: Remedesivir, SARS-CoV-2, Food and drug administration (FDA), MERS-CoV-2, Clinical trials.

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Savithri Somala Articles by Bhavani Yelicherla Articles by Salma Shaik
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

SS, BY, Shaik S. A REVIEW ON UTILISATION OF REMDESIVIR IN TREATING COVID 19 : THERAPEUTIC REPURPOSING AND UNMET CLINICAL NEEDS. IJPRT. 2022; 12(2): 32-38. doi:10.31838/ijprt/12.02.05

Web Style

SS, BY, Shaik S. A REVIEW ON UTILISATION OF REMDESIVIR IN TREATING COVID 19 : THERAPEUTIC REPURPOSING AND UNMET CLINICAL NEEDS. https://www.ijprt.org/?mno=135819 [Access: June 25, 2022]. doi:10.31838/ijprt/12.02.05

AMA (American Medical Association) Style

SS, BY, Shaik S. A REVIEW ON UTILISATION OF REMDESIVIR IN TREATING COVID 19 : THERAPEUTIC REPURPOSING AND UNMET CLINICAL NEEDS. IJPRT. 2022; 12(2): 32-38. doi:10.31838/ijprt/12.02.05

Vancouver/ICMJE Style

SS, BY, Shaik S. A REVIEW ON UTILISATION OF REMDESIVIR IN TREATING COVID 19 : THERAPEUTIC REPURPOSING AND UNMET CLINICAL NEEDS. IJPRT. (2022), [cited June 25, 2022]; 12(2): 32-38. doi:10.31838/ijprt/12.02.05

Harvard Style

, S. S., , . B. Y. & Shaik, . S. (2022) A REVIEW ON UTILISATION OF REMDESIVIR IN TREATING COVID 19 : THERAPEUTIC REPURPOSING AND UNMET CLINICAL NEEDS. IJPRT, 12 (2), 32-38. doi:10.31838/ijprt/12.02.05

Turabian Style

, Savithri Somala, Bhavani Yelicherla, and Salma Shaik. 2022. A REVIEW ON UTILISATION OF REMDESIVIR IN TREATING COVID 19 : THERAPEUTIC REPURPOSING AND UNMET CLINICAL NEEDS. International Journal of Pharmacy Research & Technology, 12 (2), 32-38. doi:10.31838/ijprt/12.02.05

Chicago Style

, Savithri Somala, Bhavani Yelicherla, and Salma Shaik. "A REVIEW ON UTILISATION OF REMDESIVIR IN TREATING COVID 19 : THERAPEUTIC REPURPOSING AND UNMET CLINICAL NEEDS." International Journal of Pharmacy Research & Technology 12 (2022), 32-38. doi:10.31838/ijprt/12.02.05

MLA (The Modern Language Association) Style

APA (American Psychological Association) Style

, S. S., , . B. Y. & Shaik, . S. (2022) A REVIEW ON UTILISATION OF REMDESIVIR IN TREATING COVID 19 : THERAPEUTIC REPURPOSING AND UNMET CLINICAL NEEDS. International Journal of Pharmacy Research & Technology, 12 (2), 32-38. doi:10.31838/ijprt/12.02.05

Most Viewed Articles

Stability Indicating HPLC Method for Simultaneous Estimation of Nicotinamide and Salicylic Acid
FALGUNI TANDEL, PRATIMA MORE
IJPRT. 2018; 8(2): 43-47
» Abstract » doi: 10.31838/ijprt/08.02.05

FORMULATION AND EVALUATION OF NANO PARTICULATE DRUG DELIVERY SYSTEM FOR AN EFFECTIVE TREATMENT OF ACNE
ISHRAT S. CHHOWALA, DEVARSHI MADHUBHAI JANI, DR ABHAY DHARAMSI, DR. GAJANAN SHINDHE, DR. RAKESH PATEL.
IJPRT. 2018; 8(2): 14-26
» Abstract » doi: 10.31838/ijprt/08.02.02

Antimicrobial activities, antioxidant and phytochemical analysis of methanol and aqueous leaf extract of Phyllathus muellerianus (KUNTZ) Exell
FRED COOLBORN AKHARAIYI* ,ABAYOMI OLABANJO DINA
IJPRT. 2018; 8(1): 29-38
» Abstract » doi: 10.31838/ijprt/08.01.04

Pharmacovigilance system and the future challenges in India-A Perspective
*SANDHYA JAIN*, 1DR VIKAS JAIN, 2RADHA SHARMA
IJPRT. 2018; 8(2): 27-31
» Abstract » doi: 10.31838/ijprt/08.02.03

Piperine : A Bioenhancer
Amar Singh*, Amar Deep
IJPRT. 2011; 1(1): 1-5
» Abstract » doi: 10.31838/ijprt/01.01.01

Most Downloaded

RELEASE KINETICS CONCEPTS AND APPLICATIONS
M. PADMAA PAARAKH , PREETHY ANI JOSE* , CM SETTY , G.V. PETER CHRISTOPER
IJPRT. 2018; 8(1): 12-20
» Abstract » doi: 10.31838/ijprt/08.01.02

FORMULATION AND EVALUATION OF ACTIVATED CHARCOAL PEEL OFF MASK
SWETA V.KULKARNI*, DR.ARUN K.GUPTA, SHUBHAM BHAWSAR
IJPRT. 2019; 9(2): 44-48
» Abstract » doi: 10.31838/ijprt/09.02.06

A case report on sympneumonic effusion
Sandeep Akkam, Pooja dasari, Nandini Thota,
IJPRT. 2021; 11(2): 17-18
» Abstract » doi: 10.31838/ijprt/11.02.02

Medicinal vegetal use by traditional healers in Ekiti State of Nigeria for diabetes treatment
AKHARAIYI, FRED COOLBORN , ADEROBA ADEYEMI ADEGBEMISIPO
IJPRT. 2018; 8(1): 21-28
» Abstract » doi: 10.31838/ijprt/08.01.03

Most Cited Articles

Piperine : A Bioenhancer
Amar Singh*, Amar Deep
IJPRT. 2011; 1(1): 1-5
» Abstract » doi: 10.31838/ijprt/01.01.01
Cited : 5 times [Click to see citing articles]

Biodiversity and conservation Ferns Diversity in different forests of Dehradun district
CHHAYA SINGH, BRIJESH KUMAR, ANJU RANI, KAMLA DHYANI, RAJ SINGH
IJPRT. 2017; 7(2): 01-07
» Abstract » doi: 10.31838/ijprt/07.02.01
Cited : 3 times [Click to see citing articles]

A Preliminary Investigation of Moringa Oleifera Lam Gum As a Pharmaceutical Excipient
Dhiren P Shah*, Vineet C Jain, Hitesh P Dalvadi, Vinod D Ramani, Kajal G Patel, Mahesh G Saralai, Girish K Jani
IJPRT. 2011; 1(1): 12-16
» Abstract » doi: 10.31838/ijprt/01.01.03
Cited : 2 times [Click to see citing articles]

EFFECT OF SEED EXTRACTS OF Elettaria cardamomum ON CALCIUM OXALATE CRYSTALLIZATION
Manish A. Patel, Paras K. Patel, Dr. Avinash K Seth
IJPRT. 2011; 1(1): 21-25
» Abstract » doi: 10.31838/ijprt/01.01.05
Cited : 2 times [Click to see citing articles]

This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access. The articles in International Journal of Pharmacy Research & Technology are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

Copyright � 2022 International Journal of Pharmacy Research & Technology All Rights Reserved. Subject to change without notice from or liability to International Journal of Pharmacy Research & Technology. For best results, please use Internet Explorer or Google Chrome	Contact Information International Journal of Pharmacy Research & Technology (IJPRT) C/O Advanced Scientific Research, 21 Thamotharan Street, Salem, Tamilnadu-636009 Phone: +91-6383437191 Email : ijprtjournal@gmail.com

POLICIES & JOURNAL LINKS

Contact Information

How to cite this article